CATALYST PHARMACEUTICALS INC. - COMMON STOCK

Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024

22 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

28 Mar 2024 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

27 Mar 2024 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

13 Mar 2024 07:55:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

05 Mar 2024 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

28 Feb 2024 18:03:23 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

27 Feb 2024 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

21 Feb 2024 09:00:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

14 Feb 2024 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering

09 Jan 2024 16:05:13 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

05 Jan 2024 08:02:06 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

04 Jan 2024 16:49:58 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma

18 Dec 2023 06:30:03 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies

05 Dec 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions

04 Dec 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference

16 Nov 2023 08:05:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update

08 Nov 2023 16:11:02 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®

02 Nov 2023 10:37:31 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo

30 Oct 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

26 Oct 2023 15:19:11 By Nasdaq GlobeNewswire